Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty.
Combination lovastatin and probucol reduced total cholesterol (27%) and low-density lipoprotein levels (30%), but did not prevent restenosis or clinical events during the first 6 months after percutaneous transluminal coronary angioplasty.
O'Keefe
J H
JH
Mid America Heart Institute, St. Luke's Hospital, Kansas City, Missouri, USA.
Stone
G W
GW
McCallister
B D
BD
Maddex
C
C
Ligon
R
R
Kacich
R L
RL
Kahn
J
J
Cavero
P G
PG
Hartzler
G O
GO
McCallister
B D
BD
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003251:Constriction, Pathologic; D003327:Coronary Disease / Q000097:blood / Q000601:surgery*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000627:therapeutic use*; D012008:Recurrence
D000924:Anticholesteremic Agents; D008074:Lipoproteins; D008148:Lovastatin; D011341:Probucol